Definium Therapeutics, Inc. (DFTX) shares surged 49.73 percent, gaining $12.17 to $36.65 on Monday, after the company reported positive topline results from its Phase 3 Emerge study evaluating DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
The stock is currently trading at $36.65, compared with its previous close of $24.48 on the Nasdaq. During the session, shares opened at $38.74 and traded between $35.13 and $39.16. Trading volume reached 11.61 million shares, well above the average daily volume of 1.92 million shares.
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in depression symptoms compared with placebo, with results showing rapid and durable benefits through 12 weeks.
Definium's 52-week range is $6.34 to $39.16.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.